Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
22%(2 trials)

Phase Distribution

Ph phase_4
3
33%
Ph phase_3
3
33%
Ph not_applicable
1
11%
Ph phase_2
2
22%

Phase Distribution

0

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
3(33.3%)
Phase 4Post-market surveillance
3(33.3%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (22.2%)
Phase 33 (33.3%)
Phase 43 (33.3%)
N/A1 (11.1%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

NCT04502966
completedphase_4

Tolerability of Grazax in Patients With Hayfever in Real Life Settings

NCT01433510
completednot_applicable

Standardising Nasal Allergen Challenge in Adult With Hay Fever

NCT04078009
completedphase_2

Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study

NCT02005627
completedphase_4

Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

NCT02437786
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04502966Phase 2

Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction

Completed
NCT01433510Phase 4

Tolerability of Grazax in Patients With Hayfever in Real Life Settings

Completed
NCT04078009Not Applicable

Standardising Nasal Allergen Challenge in Adult With Hay Fever

Completed
NCT02005627Phase 2

Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study

Completed
NCT02437786Phase 4

Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

Completed
NCT01854736Phase 4

Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate

Completed
NCT01061203Phase 3

Grazax Asthma Prevention

Completed
NCT00421655Phase 3

A Trial of Grazax in Subjects With Hayfever

Completed
NCT00773240Phase 3

A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9